154 related articles for article (PubMed ID: 37697668)
21. Proton beam therapy for extrahepatic biliary tract cancer: Analysis with prospective multi-institutional patients' registration database, Proton-Net.
Yamazaki H; Shibuya K; Kimoto T; Suzuki M; Murakami M; Terashima K; Okimoto T; Iizumi T; Sakurai H; Wakatsuki M; Suzuki O; Katoh N; Arimura T; Ogino T; Takagi M; Araya M; Waki T; Matsumoto S; Ogino H; Fukumoto T; Ohtsuka M
Clin Transl Radiat Oncol; 2023 Jul; 41():100634. PubMed ID: 37234735
[TBL] [Abstract][Full Text] [Related]
22. Chest wall toxicity after hypofractionated proton beam therapy for liver malignancies.
Yeung R; Bowen SR; Chapman TR; MacLennan GT; Apisarnthanarax S
Pract Radiat Oncol; 2018; 8(4):287-293. PubMed ID: 29452863
[TBL] [Abstract][Full Text] [Related]
23. Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies.
Badiyan SN; Rutenberg MS; Hoppe BS; Mohindra P; Larson G; Hartsell WF; Tsai H; Zeng J; Rengan R; Glass E; Katz S; Vargas C; Feigenberg SJ; Simone CB
Pract Radiat Oncol; 2019; 9(4):280-288. PubMed ID: 30802618
[TBL] [Abstract][Full Text] [Related]
24. A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases.
Kim K; Yu JI; Park HC; Yoo GS; Lim DH; Noh JM; Jeong WK
Radiother Oncol; 2022 Nov; 176():9-16. PubMed ID: 36113779
[TBL] [Abstract][Full Text] [Related]
25. Clinical Impact of Proton Beam Therapy for Postoperative Lymph Node Oligorecurrence of Esophageal Cancer.
Hiroshima Y; Ishikawa H; Sumiya T; Murakami M; Nakamura M; Ishida T; Ogawa K; Hisakura K; Mizumoto M; Oda T; Okumura T; Sakurai H
In Vivo; 2023; 37(3):1253-1259. PubMed ID: 37103111
[TBL] [Abstract][Full Text] [Related]
26. Clinical Outcomes and Prognostic Factors of High-Dose Proton Beam Therapy for Peripheral Stage I Non-Small-Cell Lung Cancer.
Hatayama Y; Nakamura T; Suzuki M; Azami Y; Ono T; Yabuuchi T; Hayashi Y; Kimura K; Hirose K; Wada H; Hareyama M; Kikuchi Y; Takai Y
Clin Lung Cancer; 2016 Sep; 17(5):427-432. PubMed ID: 26725851
[TBL] [Abstract][Full Text] [Related]
27. Proton Beam Therapy With Space-Making Surgery (Omental Plombage) for Oligorecurrent Liver Metastasis of Esophageal Adenocarcinoma.
Ishikawa Y; Morita K; Yamaguchi H; Kato T; Suzuki M; Seto I; Machida M; Takayama K; Tominaga T; Takagawa Y; Nakajima M; Teranishi Y; Kikuchi Y; Murakami M
Cureus; 2022 Nov; 14(11):e31656. PubMed ID: 36415474
[TBL] [Abstract][Full Text] [Related]
28. Dose-volume histogram analysis for risk factors of radiation-induced rib fracture after hypofractionated proton beam therapy for hepatocellular carcinoma.
Kanemoto A; Mizumoto M; Okumura T; Takahashi H; Hashimoto T; Oshiro Y; Fukumitsu N; Moritake T; Tsuboi K; Sakae T; Sakurai H
Acta Oncol; 2013 Apr; 52(3):538-44. PubMed ID: 22950386
[TBL] [Abstract][Full Text] [Related]
29. Proton reirradiation for recurrent or new primary breast cancer in the setting of prior breast irradiation.
Choi JI; Khan AJ; Powell SN; McCormick B; Lozano AJ; Del Rosario G; Mamary J; Liu H; Fox P; Gillespie E; Braunstein LZ; Mah D; Cahlon O
Radiother Oncol; 2021 Dec; 165():142-151. PubMed ID: 34688807
[TBL] [Abstract][Full Text] [Related]
30. Proton Beam Therapy for Histologically or Clinically Diagnosed Stage I Non-Small Cell Lung Cancer (NSCLC): The First Nationwide Retrospective Study in Japan.
Ohnishi K; Nakamura N; Harada H; Tokumaru S; Wada H; Arimura T; Iwata H; Sato Y; Sekino Y; Tamamura H; Mizoe JE; Ogino T; Ishikawa H; Kikuchi Y; Okimoto T; Murayama S; Akimoto T; Sakurai H
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):82-89. PubMed ID: 31580927
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of Japanese nationwide cohort data of particle beam therapy for pulmonary, liver and lymph node oligometastases: particle beam therapy versus high-precision X-ray radiotherapy.
Aibe N; Ogino H; Wakatsuki M; Fujikawa K; Teramukai S; Fukumitsu N; Shiba S; Yamamoto N; Nomoto A; Ono T; Oguri M; Yamaguchi H; Numajiri H; Shibuya K; Okazaki S; Miyasaka Y; Okonogi N; Murata K; Tatebe H; Motegi A; Okimoto T; Yoshino T; Mandai M; Katoh N; Tsuji H; Sakurai H
J Radiat Res; 2023 Jun; 64(Supplement_1):i69-i83. PubMed ID: 37053162
[TBL] [Abstract][Full Text] [Related]
32. Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer.
Harada H; Fuji H; Ono A; Kenmotsu H; Naito T; Yamashita H; Asakura H; Nishimura T; Takahashi T; Murayama S
Cancer Sci; 2016 Jul; 107(7):1018-21. PubMed ID: 27110950
[TBL] [Abstract][Full Text] [Related]
33. Hypofractionated proton beam therapy for centrally located lung cancer.
Nakamura N; Hotta K; Zenda S; Baba H; Kito S; Akita T; Motegi A; Hojo H; Nakamura M; Parshuram RV; Okumura M; Akimoto T
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):552-556. PubMed ID: 31145553
[TBL] [Abstract][Full Text] [Related]
34. Outcomes and prognostic factors for recurrence after high-dose proton beam therapy for centrally and peripherally located stage I non--small-cell lung cancer.
Kanemoto A; Okumura T; Ishikawa H; Mizumoto M; Oshiro Y; Kurishima K; Homma S; Hashimoto T; Ohkawa A; Numajiri H; Ohno T; Moritake T; Tsuboi K; Sakae T; Sakurai H
Clin Lung Cancer; 2014 Mar; 15(2):e7-12. PubMed ID: 24365049
[TBL] [Abstract][Full Text] [Related]
35. Proton Beam Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study in Japan.
Mizumoto M; Terashima K; Makishima H; Suzuki M; Ogino T; Waki T; Iwata H; Tamamura H; Uchinami Y; Akimoto T; Okimoto T; Iizumi T; Murakami M; Katoh N; Maruo K; Shibuya K; Sakurai H
Liver Cancer; 2024 Apr; 13(2):161-168. PubMed ID: 38751552
[TBL] [Abstract][Full Text] [Related]
36. High-dose proton beam therapy for stage I non-small cell lung cancer: Clinical outcomes and prognostic factors.
Makita C; Nakamura T; Takada A; Takayama K; Suzuki M; Azami Y; Kato T; Tsukiyama I; Hareyama M; Kikuchi Y; Daimon T; Hata M; Inoue T; Fuwa N
Acta Oncol; 2015 Mar; 54(3):307-14. PubMed ID: 25291076
[TBL] [Abstract][Full Text] [Related]
37. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer.
Lin SH; Hobbs BP; Verma V; Tidwell RS; Smith GL; Lei X; Corsini EM; Mok I; Wei X; Yao L; Wang X; Komaki RU; Chang JY; Chun SG; Jeter MD; Swisher SG; Ajani JA; Blum-Murphy M; Vaporciyan AA; Mehran RJ; Koong AC; Gandhi SJ; Hofstetter WL; Hong TS; Delaney TF; Liao Z; Mohan R
J Clin Oncol; 2020 May; 38(14):1569-1579. PubMed ID: 32160096
[TBL] [Abstract][Full Text] [Related]
38. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD
JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865
[TBL] [Abstract][Full Text] [Related]
39. Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma.
Iizumi T; Okumura T; Sekino Y; Takahashi H; Tsai YL; Takizawa D; Ishida T; Hiroshima Y; Nakamura M; Shimizu S; Saito T; Numajiri H; Mizumoto M; Nakai K; Sakurai H
J Radiat Res; 2021 Jul; 62(4):682-687. PubMed ID: 34036362
[TBL] [Abstract][Full Text] [Related]
40. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes.
McAvoy S; Ciura K; Wei C; Rineer J; Liao Z; Chang JY; Palmer MB; Cox JD; Komaki R; Gomez DR
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):819-27. PubMed ID: 25220718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
